Skip to main content

Health-Related Quality of Life in Inflammatory Bowel Disease

PharmacoEconomics volume 10, pages 327–335 (1996)Cite this article

Summary

Inflammatory bowel disease (IBD) is characterised by a chronic, but frequently remitting, clinical course involving significant morbidity. As medical and surgical advances have occurred, focus has shifted from merely reducing mortality to efforts on decreasing morbidity and improving health status. With this paradigm shift has come the need for qualitative and quantitative assessment of outcomes important to the individual patient. Existing disease activity measures fall short in this area.

Health-related quality of life encompasses the areas of physical function, somatic sensation, psychological state and social interactions that are affected by one’s health status. Instruments have recently been developed for both generic and disease-specific health states, such as IBD. These psychometric measures have proven to be useful tools for patient assessment. Both medical and surgical trials have incorporated these measures as salient outcomes. An additional outcome that has come under closer scrutiny is the cost of medical interventions. The literature on the cost of IBO is sparse but is likely to increase logarithmically in the future. Quality of life and cost issues are becoming central to the study of not just IBO but all of medicine.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

49,54 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

References

  1. Best WR, Becktel JM, Singleton JW. Rederived values of the eight coefficients of the Crohn’s disease activity index(COAI). Gastroenterology 1979; 77: 843–6

    PubMed  CAS  Google Scholar 

  2. Harvey RF, Bradshaw JM. A simple index of Crohn’s disease activity. Lancet 1980; 1: 514–5

    PubMed  Article  CAS  Google Scholar 

  3. Truelove SC, Witts U. Cortisone in ulcerative colitis: preliminary report in a therapeutic trial. BMJ 1954; 2: 374–8

    Article  Google Scholar 

  4. Hodgson HJF, Mazlam MZ. Review article: assessment of drug therapy in inflammatory bowel disease. Aliment Pharmacol Ther 1991; 5: 555–84

    PubMed  Article  CAS  Google Scholar 

  5. Calkins BM, Mendeloff AI. Epidemiology of inflammatory bowel disease. Epidemiol Rev 1986; 8: 60–91

    PubMed  CAS  Google Scholar 

  6. Sandler RS, Golden AL. Epidemiology of Crohn’s disease. J Clin Gastroenterol 1986; 8: 160–8

    PubMed  Article  CAS  Google Scholar 

  7. Farmer RG, Hawk WA, Turnbull RB. Clinical patterns in Crohn’s disease: a statistical study of 615 patients. Gastroenterology 1975; 68: 627–35

    PubMed  CAS  Google Scholar 

  8. Shumaker SA, Anderson RT, Czajkowski SM. Psychological test and scales. In: Spilker B, editor. Quality of life assessmentin clinical trials. New York: Raven Press, 1990: 95–114

    Google Scholar 

  9. Kirshner B, Guyall GH. A methodological framework for assessing health indices. J Chronic Dis 1988; 38: 27–36

    Article  Google Scholar 

  10. Barofsky I, Sugarbaker PH. Cancer. In: Spilker B, editor. Quality oflife assessment in clinical trials. New York: Raven Press, 1990: 419–40

    Google Scholar 

  11. Stewart AI, Greenfield S, Hays RD, et al. Functional status and well—being of patients with chronic conditions: results from the Medical Outcomes Study. JAMA 1989; 262: 907–13

    PubMed  Article  CAS  Google Scholar 

  12. Bergner M, Bobbitt RA, Pollard M, et al. The sickness impact profile: validation of a health status measure. Med Care 1976; 14: 57–67

    PubMed  Article  CAS  Google Scholar 

  13. Singleton JW, Hanauer S, Robinson M. Quality of life results of a double blind, placebo controlled trial of mesalamine inpatients with Crohn’s disease. Dig Dis Sci 1995; 40: 931–5

    PubMed  Article  CAS  Google Scholar 

  14. Guyall G, Mitchell A, Irvine EJ, et al. A new measure of health status for clinical trials in IBD. Gastroenterology 1989; 96: 804–10

    Google Scholar 

  15. Love JR, Irvine EJ, Fedorak RN. Quality oflife in inflammatory bowel disease. J Clin Gastroenterol 1992; 14: 15–9

    PubMed  Article  CAS  Google Scholar 

  16. Farmer RG, Easley KA, Farmer JM. Quality of life assessment by patients with inflammatory bowel disease. Cleve Clin J Med 1992; 59: 35–42

    PubMed  CAS  Google Scholar 

  17. Drossman DA, Leserman J, Li Z, et al. The rating form of IBD patient concerns: a new measure of health status. Psychosom Med 1991; 53: 701–12

    PubMed  CAS  Google Scholar 

  18. Drossman DA, Li Z, Leserman J, et al. Ulcerative Colitis and Crohn’s Disease Health Status scales for research and clinicalpractice. J Clin Gastroenterol 1992; 15: 104–12

    PubMed  Article  CAS  Google Scholar 

  19. Mcleod RS, Cohen Z, Churchill DN, et al. Measurement of quality of life of patients with ulcerative colitis undergoingsurgery. Gastroenterology 1991; 101: 1307–13

    PubMed  CAS  Google Scholar 

  20. Welch G, Richter J, Kawachi I, et al. The SF−36 quality of life measure in inflammatory bowel disease: an evaluation of itsreliability and validity [abstract). Gastroenterology 1995; 108: A940

    Article  Google Scholar 

  21. Drossman OA, Patrick OL, Mitchell CM, et al. Health—related quality of life in inflammatory bowel disease: functional statusand patient worries and concerns. Dig Dis Sci 1989; 34: 1379–86

    PubMed  Article  CAS  Google Scholar 

  22. Drossman DA, Leserman J, Mitchell CM, et al. Health status and health care use in persons with inflammatory bowel disease:a national sample. Dig Dis Sci 1991; 36: 1746–55

    PubMed  Article  CAS  Google Scholar 

  23. Folkman S, Lazarus RS, Gruen RJ, et al. Appraisal, coping, heallh status, and psychological symptoms. J Pers Soc Psychol 1986; 50: 571–9

    PubMed  Article  CAS  Google Scholar 

  24. Mitchell AM, Guyau G, Singer J. et al. Quality oflife in patients with inflammatory bowel disease. J Clin Gastroenterol 1988; 10: 306–10

    PubMed  Article  CAS  Google Scholar 

  25. Irvine EJ, Feagan B, Rochon J, et al. Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Gastroenterology 1994; 106: 287–96

    PubMed  CAS  Google Scholar 

  26. Van Hees PAM, van Elleren PH, van Lier JJ, et al. An index of inflammatory activity in patients with Crohn’s disease. Gut 1980; 21: 279–84

    PubMed  Article  Google Scholar 

  27. Powell-Tuck J, Day DW, Bucknell NA, et al. Correlations between defined sigmoidoscopic appearances and other measuresof disease activity in ulcerative colitis. Dig Dis Sci 1982; 27: 533–7

    PubMed  Article  CAS  Google Scholar 

  28. Feagan BG, Mc Donald JWD, Rochon J. et al. Low dose cyclosporine for the treatment of Crohn’s disease. N Engl J Med 1994; 330: 1846–51

    PubMed  Article  CAS  Google Scholar 

  29. Greenberg GR, Feagan BG, Martin F, et al. Oral budesonide for active Crohn’s disease. N Engl J Med 1994; 331: 836–41

    PubMed  Article  CAS  Google Scholar 

  30. Feagan BG, Rochon J, Fedorak RN, et al. Methotrexate for the treatment of Crohn’s disease. N Engl J Med 1995; 332: 292–7

    PubMed  Article  CAS  Google Scholar 

  31. Irvine EJ, Zhou Q. Thompson AK and the CCRPT investigators. The short inflammatory bowel disease questionnaire: aquality of life instrument for community physicians managinginflammatory bowel disease. Am J Gastroenterol 1996; 91 (8): 1571–8

    PubMed  CAS  Google Scholar 

  32. Jaeschke R, Guyatt GH, Cook D. Quality of life instruments in the evaluation of new drugs. Pharmacoeconomics 1992; 1: 84–94

    PubMed  Article  CAS  Google Scholar 

  33. Derogatis LR. SCL−90−R: administration, scoring and procedures manual II—for the revised version. Towson: Clinical Psychometric Research. 1983

    Google Scholar 

  34. Talal AH, Drossman DA. Psychosocial factors in inflammatory bowel disease. Gastroenterol C1in North Am 1995: 24 (3): 699–716

    Google Scholar 

  35. Drossman DA. Inflammatory bowel disease. In: Spilker B. editor. Quality of life and pharrnacoeconomics in clinical trials. New York: Lippincott Raven Press. 1996: 925–36

    Google Scholar 

  36. Morowitz DA, Kirsner JB. Ileostomy in ulcerative colitis: a questionnaire study of 1.083 patients. Am J Surg 1981; 141: 370–5

    PubMed  Article  CAS  Google Scholar 

  37. Roy PH, Sauer WG, Beahrs OH, et al. Experience with ileostomies: evaluation of long—term rehabilitation in 497 patients. Am J Surg 1970; 119: 77–86

    PubMed  Article  CAS  Google Scholar 

  38. Mc Leod RS. Quality of life assessment in gastrointestinal surgery. In: Spilker B, editor. Quality of life and pharmacoeconomicsin clinical trials. New York: Lippincott Raven Press. 1996

    Google Scholar 

  39. Torrance GW, Thomas WH, Sackell DL. A utility maximization model for the evaluation of health care programs. Health Serv Res 1972; 7: 118–33

    PubMed  CAS  Google Scholar 

  40. Farmer RG. Human cost of inflammatory bowel disease. Can J Gastroenterol 1994: 8: 140–4

    Google Scholar 

  41. Brown DM, Everhart JE. Cost of digestive diseases in the United States. In: Everhart JE, editor. Digestive diseases in the United States: epidemiology and impact, U.S. Department of Health and Human Services, Public Health Service, NationalInstitutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. Washington D.C.: US GovernmentPrinting Office. 1994: NIH publication no. 94-1447: 57–81

    Google Scholar 

  42. Hay JW, Hay AR. Inflammatory bowel disease: costs of illness. J Clin Gastroenterol 1992; 14: 309–17

    PubMed  Article  CAS  Google Scholar 

  43. Wennberg JE. Outcomes research, cost containment and the fear of health care rationing. N Engl J Med 1990: 323: 1202–4

    PubMed  Article  CAS  Google Scholar 

  44. Guyatt GH, Feeny DH, Patrick DL. Measuring health related quality of life. Ann Intern Med 1993: 118: 622–9

    PubMed  CAS  Google Scholar 

  45. Feeny D, Labelle R, Torrance GW. Integrating economic evaluations and quality of life assessments. In: Spilker B, editor. Quality of life assessments in clinical trials. New York: Raven Press. 1990: 71–83

    Google Scholar 

  46. Drummond MF, Stoddart GL, Torrance GW. Methods for economic evaluation of health care programmes. Oxford: Oxford University Press. 1987

    Google Scholar 

Download references

Author information

Affiliations

  1. Department of Medicine, Division of Gastroenterology, Georgetown University Medical Center, 3800 Reservoir Road NW, Washington DC, 20007-2197, USA

    Glenn M. Eisen & Richard G. Farmer

Authors
  1. Glenn M. Eisen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Richard G. Farmer
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Eisen, G.M., Farmer, R.G. Health-Related Quality of Life in Inflammatory Bowel Disease. Pharmacoeconomics 10, 327–335 (1996). https://doi.org/10.2165/00019053-199610040-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00019053-199610040-00003

Keywords

  • Inflammatory Bowel Disease
  • Ulcerative Colitis
  • Inflammatory Bowel Disease Patient
  • Mesalamine
  • Sickness Impact Profile